Literature DB >> 23894122

Down-staging of hepatocellular carcinoma via external-beam radiotherapy with subsequent liver transplantation: a case report.

Alan Wigg1, Kenneth Hon, Leigh Mosel, Nicole Sladden, Kevin Palumbo.   

Abstract

Despite the widespread use of locoregional therapies [radiofrequency ablation and transarterial chemoembolization (TACE)], there is currently a lack of high-quality evidence supporting their use for hepatocellular carcinoma (HCC) in patients on the liver transplantation (LT) waiting list or requiring down-staging. Radiotherapy has rarely been used in this setting and has usually been in the form of more complex and less accessible techniques such as proton-beam and stereotactic body radiation therapy. Only 1 report describes the use of conventional 3-dimensional conformal external-beam radiotherapy (cEBRT) techniques as neoadjuvant or down-staging therapy for patients who are LT candidates. This report describes the use of cEBRT in a 52-year-old hepatitis C-positive man with cirrhosis. A 40-mm right lobe HCC was treated initially with TACE while he was on the waiting list. The lesion progressed beyond transplant criteria (76 mm). Conventional external-beam radiotherapy (EBRT) was used (54 Gy in 27 fractions) to down-stage the lesion. EBRT was well tolerated and resulted in a complete radiological response with no arterial enhancement of the lesion for a total of 16 months. Subsequent LT and a review of the explant demonstrated complete histological necrosis of the lesion. This report provides the first description of complete histological necrosis of HCC through the use of cEBRT techniques as down-staging/neoadjuvant therapy before LT. Because of its potential efficacy, accessibility, tolerability, noninvasive and outpatient nature, and ability to treat lesions adjacent to vessels and biliary structures, further trials examining the efficacy of cEBRT versus other neoadjuvant techniques are urgently required.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23894122     DOI: 10.1002/lt.23714

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  3 in total

Review 1.  Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.

Authors:  Nitin Ohri; Laura A Dawson; Sunil Krishnan; Jinsil Seong; Jason C Cheng; Shiv K Sarin; Milan Kinkhabwala; Mansoor M Ahmed; Bhadrasain Vikram; C Norman Coleman; Chandan Guha
Journal:  J Natl Cancer Inst       Date:  2016-07-04       Impact factor: 13.506

2.  Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.

Authors:  Ik Jae Lee; Jun Won Kim; Kwang Hyub Han; Ja Kyung Kim; Kyung Sik Kim; Jin Sub Choi; Young Nyun Park; Jinsil Seong
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

3.  Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study.

Authors:  Vassilis Kouloulias; Eftychia Mosa; John Georgakopoulos; Kalliopi Platoni; Ilias Brountzos; Anna Zygogianni; Christos Antypas; Paraskevas Kosmidis; Kyriaki Mystakidou; Maria Tolia; Ivelina Beli; Athanasios Gouliamos; John Kouvaris; Nikoalos Kelekis
Journal:  ScientificWorldJournal       Date:  2013-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.